Navigation Links
Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:10/1/2008

ATLANTA, Oct. 1 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim month six safety and efficacy results from the first human pharmacokinetic (PK) study of Iluvien(TM).

Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME). DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

This 36-month, open-label, Phase 2 PK study, running concurrently with the pivotal Phase 3 FAME(TM) Study of Iluvien (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide, after administration of Iluvien in patients with DME. Secondarily, the PK study is designed to provide information on the safety and efficacy of Iluvien in a DME patient population. A total of 37 subjects were enrolled in the PK study, 20 patients on the low dose of Iluvien (an approximate 0.23 micrograms per day dose), and 17 patients on the high dose of Iluvien (an approximate 0.45 micrograms per day dose).

The six-month interim readout from the PK study showed 18 percent of the high dose patients had an improvement in best corrected visual acuity (BCVA) of 15 letters or greater over baseline. This is consistent with the three- month readout. The percentage of low dose patients that had an improvement in BCVA of 15 letters or greater from baseline decreased from
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
8. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
11. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Hill-Rom Holdings, Inc. (NYSE: HRC ) will release ... 2011.  The company will host a webcast the following morning ... Earnings Release:   Hill-Rom,s Fiscal 2011 Third Quarter ... be issued to the public after the close of the ...
... 2011 U.S. Senators Jerry Moran ... established the first-ever Senate Community Pharmacy Caucus, an effort ... (NCPA). (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO) The ... pharmacy issues while serving as a clearinghouse of ideas ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 Third Quarter Earnings Webcast 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 3
(Date:4/16/2014)... , While it is well known that fertility treatments ... and that multiples are at elevated risk of premature ... in Fertility and Sterility . The ... can reduce the odds of multiple births and prematurity, ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found a ... about 1.5 million people a year. The researchers say they now ... has been in use for more than 50 years even ... is to the microbes it attacks. , A report ...
(Date:4/14/2014)... advances have been made in chemotherapy over the past ... healthy tissues continues to be a major challenge. ... delivery, including the use of nanocarriers, or capsules, that ... in the body. , The catch? These carriers are ...
(Date:4/14/2014)... American Associations for Dental Research (IADR/AADR) have published a ... and Craniofacial Manifestations." The complete review by researchers Sunday ... Collins, Brian L. Foster, Rachel I. Gafni, Janice S. ... Timothy Wright is published in the OnlineFirst portion of ...
(Date:4/14/2014)... treatment decisions leaves cancer patients feeling more satisfied with ... the experience, researchers from the Perelman School of ... the journal Cancer . , In a study ... MD , an associate professor in the department in ...
Breaking Medicine News(10 mins):Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... with CyberKnife Radiosurgery Worldwide, SUNNYVALE, Calif., Nov. ... global leader in the field of radiosurgery,today announced ... to treat more than 4,000 lung cancer patients ... patients in total have been treated,with CyberKnife radiosurgery ...
... 25% of all,cancers are due to genetic factors, patients that ... on the lookout for the early warning signs of,cancer. This ... from,both a medical and psychological prospective. Cancer does run ... Today, suggests it is misleading to think of cancer as ...
... (NYSE: SGP ) today announced that it ... Commission (FTC) regarding its,planned acquisition of Organon BioSciences ... 2007. Organon BioSciences is comprised mainly of ... health business. It also,includes Nobilon, the human vaccine ...
... of Georgia Drug Agency Approves Protocol for New Clinical ... of Bavituximab in Combination with ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company ... C virus (HCV) infection, today announced that its Phase ...
... following is being,issued by the National Council on Disability:, ... to December 1, 2007., WHERE:, Hyatt Regency Boston ... November 29, 2007, 8:30 a.m. - 10:00 a.m. ... Vaughn -- Introduction of Council Members, NCD staff and ...
... 16 21st Services has created its,first Medical Advisory ... an innovative approach in the life settlement industry. ... the sophistication,of its underwriting model and its life expectancy ... up of physicians from,across the country who are experts ...
Cached Medicine News:Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 2Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 3Health News:Genetics and Risk, This Week on Your Cancer Today(TM) 2Health News:Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V. 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 2Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 3Health News:In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk 2
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
... the osteotomy staples is quite similar to the type ... inner position of the anti recoil contours and the ... There are 3 kinds of staples: 1. Straight ... staples can have 3 different widths: 20mm, 26 mm ...
A new generation of ORTHOMED S.A. fixation staples, manufactured from cobalt-chromium alloy: tried and test strength and tolerance...
Medicine Products: